<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Companion diagnostic partnering

Our companion diagnostic (CDx) development partnering capabilities supports biopharma partners with superior CDx solutions to help overcome the challenges associated with identifying the right patient for the right drug in clinical development and after approval for commercialization.

CDx partnering solutions process

Joint Companion Diagnostic Partnering Solution

We provide end-to-end CDx partnering solutions for our biopharma customers from initial biomarker discovery to commercialization.

Why is Dx Companion Diagnostics Partnering Beneficial?

Increase probability of success for pivotal trials
Potentially accelerate FDA approval of therapeutics
Identify patient populations who may experience benefit from new therapeutics for approved therapeutics in clinical development
Realize greater efficiency in clinical development from faster patient enrollment in clinical trials
Benefit from Biodesix’s flexible regulatory and commercialization strategies that can include a single site and distributed strategy for test commercialization
Benefit from Biodesix’s commercial and reimbursement experience in diagnostics

Why Partner With Us?

  • We can structure our CDx partnership model to fit your needs
  • We actively engage in IVD programs in the US and ROW
  • We provide a multiple technology approach to biomarker discovery, development,regulatory approval and commercialization of diagnostic tests
  • We have significant experience gaining wide-spread U.S. reimbursement for novel diagnostic tests
  • We have two laboratories that maintain the highest level of compliance exceeding the minimal clinical laboratory certification
iStock-1205310201-small

Contact our biopharma services team to learn more about our capabilities to be your CDx partner